Cargando…

Combining thioridazine and loratadine for the treatment of gastrointestinal tumor

In 2015, the American Society of Clinical Oncology announced that strategies of using combination therapies have been indicated to be effective against many types of cancer. In the present study, thioridazine (THZ) was used in a combination therapy with loratadine (LOR) to target gastrointestinal tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tingting, Hu, Yunlong, Liu, Bin, Huang, Xinping, Li, Qin, Gao, Ningning, Jin, Zhenchao, Jia, Tieliu, Guo, Deyin, Jin, Guangyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649607/
https://www.ncbi.nlm.nih.gov/pubmed/29085455
http://dx.doi.org/10.3892/ol.2017.6815
_version_ 1783272570487832576
author Chen, Tingting
Hu, Yunlong
Liu, Bin
Huang, Xinping
Li, Qin
Gao, Ningning
Jin, Zhenchao
Jia, Tieliu
Guo, Deyin
Jin, Guangyi
author_facet Chen, Tingting
Hu, Yunlong
Liu, Bin
Huang, Xinping
Li, Qin
Gao, Ningning
Jin, Zhenchao
Jia, Tieliu
Guo, Deyin
Jin, Guangyi
author_sort Chen, Tingting
collection PubMed
description In 2015, the American Society of Clinical Oncology announced that strategies of using combination therapies have been indicated to be effective against many types of cancer. In the present study, thioridazine (THZ) was used in a combination therapy with loratadine (LOR) to target gastrointestinal tumor, with the aim of investigating whether combined therapy was superior to monotherapy in its antitumor effects. The antiproliferative effects on CT26.WT and MFC cells were analyzed using cell-counting kit-8 assay, and synergistic effect was assessed by combination index (Fig. 1). Annexin V and propidium iodide staining indicated the combination therapy was able to induce apoptosis and that this may be mediated via caspase-3, −9 and poly (ADP-ribose) polymerase (PARP) (Fig. 2). Antitumor activity was also evaluated in CT26.WT xenografts in BALB/c mice (Fig. 3). Furthermore, as expected, combination therapy was able to successfully inhibit the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signaling pathway (Fig. 4). These findings suggest that the combination therapy with THZ and LOR may provide a promising therapy for gastrointestinal cancer.
format Online
Article
Text
id pubmed-5649607
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56496072017-10-30 Combining thioridazine and loratadine for the treatment of gastrointestinal tumor Chen, Tingting Hu, Yunlong Liu, Bin Huang, Xinping Li, Qin Gao, Ningning Jin, Zhenchao Jia, Tieliu Guo, Deyin Jin, Guangyi Oncol Lett Articles In 2015, the American Society of Clinical Oncology announced that strategies of using combination therapies have been indicated to be effective against many types of cancer. In the present study, thioridazine (THZ) was used in a combination therapy with loratadine (LOR) to target gastrointestinal tumor, with the aim of investigating whether combined therapy was superior to monotherapy in its antitumor effects. The antiproliferative effects on CT26.WT and MFC cells were analyzed using cell-counting kit-8 assay, and synergistic effect was assessed by combination index (Fig. 1). Annexin V and propidium iodide staining indicated the combination therapy was able to induce apoptosis and that this may be mediated via caspase-3, −9 and poly (ADP-ribose) polymerase (PARP) (Fig. 2). Antitumor activity was also evaluated in CT26.WT xenografts in BALB/c mice (Fig. 3). Furthermore, as expected, combination therapy was able to successfully inhibit the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signaling pathway (Fig. 4). These findings suggest that the combination therapy with THZ and LOR may provide a promising therapy for gastrointestinal cancer. D.A. Spandidos 2017-10 2017-08-24 /pmc/articles/PMC5649607/ /pubmed/29085455 http://dx.doi.org/10.3892/ol.2017.6815 Text en Copyright: © Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Chen, Tingting
Hu, Yunlong
Liu, Bin
Huang, Xinping
Li, Qin
Gao, Ningning
Jin, Zhenchao
Jia, Tieliu
Guo, Deyin
Jin, Guangyi
Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
title Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
title_full Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
title_fullStr Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
title_full_unstemmed Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
title_short Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
title_sort combining thioridazine and loratadine for the treatment of gastrointestinal tumor
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649607/
https://www.ncbi.nlm.nih.gov/pubmed/29085455
http://dx.doi.org/10.3892/ol.2017.6815
work_keys_str_mv AT chentingting combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT huyunlong combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT liubin combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT huangxinping combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT liqin combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT gaoningning combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT jinzhenchao combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT jiatieliu combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT guodeyin combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor
AT jinguangyi combiningthioridazineandloratadineforthetreatmentofgastrointestinaltumor